Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer

Lung Cancer

Volumn 75, Issue 3, 2012, Pages 381-390

  Varlotto, J ^a,f   Medford Davis, L N ^b   Recht, A ^b,c   Flickinger, J ^d   Schaefer, E ^e   Shelkey, J ^f   Lazar, M ^f,g   Campbell, D ^f,g   Nikolov, M ^h   DeCamp, M M ⁱ  

^a PENN STATE CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

^f PENN STATE COLLEGE OF MEDICINE   (United States)

^g PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^h UNITED STATES NAVAL ACADEMY   (United States)

ⁱ NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Diabetes; Local recurrence; Non small cell lung cancer; Surgical resection

Indexed keywords

HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURGERY; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG USE; FEMALE; FISTULA; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEART INFARCTION; HEART RHYTHM; HEMOGLOBIN BLOOD LEVEL; HOSPITAL READMISSION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LENGTH OF STAY; LOBECTOMY; LUNG EMBOLISM; LUNG INFECTION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MEDIASTINITIS; METABOLIC SYNDROME X; POSTOPERATIVE COMPLICATION; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84856569198     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.07.019     Document Type: Article

References (40)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Barone B.B., Yeh H.C., Snyder C.F., Peairs K.S., Stein K.B., Derr R.L., et al. Postoperative mortality in cancer patients with preexisting diabetes. Diabetes Care 2010, 33:931-939.
3. Bianchini F., Kaaks R., Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002, 3:565-574.
4. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
5. Barone B.B., Yeh H.C., Snyder C.F., Peairs K.S., Stein K.B., Derr R.L., et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008, 300(23):2754-2764.
6. Richardson L.C., Pollack L.A. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005, 2(1):48-53.
7. Giovannucci E., Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007, 132(6):2208-2225.
8. Schiel R., Beltschikow W., Steiner T., Stein G. Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 2006, 28(3):169-175.
9. Varlotto J.M., Recht A., Flickinger J.C., Medford-Davis L.N., Dyer A.M., DeCamp M.M. Factors associated with local and distant recurrence and survival in patients with resected non-small cell lung cancer. Cancer 2009, 115:1059-1069.
10. Varlotto J.M., Recht A., Flickinger J.C., Medford-Davis L.N., Dyer A.M., DeCamp M.M. Varying recurrence rates and risk factors associated with different definitions of local recurrence in patients with surgically-resected Stage I non-small cell lung cancer. Cancer 2010, 116:2390-2400.
11. Kaplan E.S., Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958, 53:475-480.
12. Cox D.R. Regression models and life tables. J R Stat Soc 1972, 34:187-220.
13. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94(446):496-509.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
15. Kim H.T. Cumulative incidence in competing risks data and competing risks regression. Clin Cancer Res 2007, 13:559-565.
16. Varlotto J.M., Medford-Davis L.N., Shelkey J.C., Flickinger J.C., Recht A., Nikolov M., et al. Surgical, histopathologic and patient-related factors associated with isolated brain metastases (IBM) in patients with stages I-IIIA non-small cell carcinoma (NSCLC) undergoing surgical resection in comparison with patients developing other distal metastases. J Clin Oncol 2011, 29. [suppl; abstr 7542].
17. Seshasai S.R., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., Sarwar N., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841.
18. Pais R., Silaghi H., Silaghi A.C., Rusu M.L., Dumitrascu D.L. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009, 15:5141-5148.
19. Pelucchi C., Negri E., Talamini R., Levi F., Giacosa A., Crispo A., et al. Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 2010, [Epub ahead of print].
20. Bjørge T., Stocks T., Lukanova A., Tretli S., Selmer R., Manjer J., et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010, 171(8):892-902.
21. Matthews C.E., Sui X., LaMonte M.J., Adams S.A., Hébert J.R., Blair S.N. Metabolic syndrome and risk of death from cancers of the digestive system. Metabolism 2009, [Epub ahead of print].
22. Lee J.S., Cho S.I., Park H.S. Metabolic syndrome and cancer-related mortality among Korean men and women. Ann Oncol 2009, 21(3):640-645.
23. Currie C.J., Peters J.R., Tynan A., Evans M., Heine R.J., Bracco O.L., et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375(9713):481-489.
24. Selvin E., Ning Y., Steffes M.W., Bash L.D., Klein R., Wong T.Y., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362(9):800-811.
25. Jee S.H., Ohrr H., Sull J.W., Yun J.E., Ji M., Samet J.M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005, 293(2):194-202.
26. Park S.M., Lim M.K., Jung K.W., Shin S.A., Yoo K.Y., Yun Y.H., et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol 2007, 25(30):4835-4843.
27. Dawson S.I. Long-term risk of malignant neoplasm associated with gestational glucose intolerance. Cancer 2004, 100(1):149-155.
28. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
29. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonlyureas or insulin. Diabetes Care 2006, 29(2):254-258.
30. Goodwin P.J., Pritchard K.I., Ennis M., Clemons M., Graham M., Fantus I.G. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008, 8(6):501-505.
31. Tosca L., Ramé C., Chabrolle C., Tesseraud S., Dupont J. Metformin decreases IGF-1-induced cell proliferation and protein synthesis through AMP-activated protein in cultured bovine granulosa cells. Reproduction 2010, 139:409-418.
32. Hazra S., Batra R.K., Tai H.H., Sharma S., Cui X., Dubinett S.M. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007, 71(6):1715-1720.
33. Govindarajan R., Ratnasinghe L., Simmons D.L., Siegel E.R., Midathada M.V., Kim L., et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007, 25(12):1476-1481.
34. Cai X.W., Xu L.Y., Wang L., Hayman J.A., Chang A.C., Pickens A., et al. Comparative survival in patients with postresection recurrent versus newly diagnosed non-small cell lung cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76(4):1100-1105.
35. Jeremic B., Shibamoto Y., Milicic B., Milisavljevic S., Nikolic N., Dagovic A., et al. External beam radiotherapy alone for loco-regional recurrence of non-small cell lung cancer after complete resection. Lung Cancer 1999, 23(2):135-142.
36. Crinò L., Weder W., van Meerbeeck J., Felip E. Early state and locally advanced (non-metastatic) non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(50):103-115. ESMO Guidelines Working Group.
37. Giraud P., Antoine M., Larrouy A., Milleron B., Callard P., De Rycke Y., et al. Evaluation of microscopic tumor extension in non-small cell lung caner for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000, 48(4):1015-1024.
38. Cowie C.C., Rust K.F., Ford E.S., Eberhardt M.S., Byrd-Holt D.D., Li C., et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
39. Harris M.I., Klein R., Welborn T.A., Knuiman M.W. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992, 15:815-819.
40. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, Decamp MM. Failure rates and patterns of recurrence in patients with N1 resected non-small cell lung cancer. Int J Radiat Oncol Biol Phys; in press.